Hassan Awada

Dr. Hassan Awada

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2018 in Leukemia
Verified
Journal Article
Closed access
PDF file
CHCassandra M. Hirsch
Cassandra M. Hirsch
ANAziz Nazha
Aziz Nazha
KKKassy Kneen
Kassy Kneen
MAMohamed E. Abazeed
Mohamed E. Abazeed
MMManja Meggendorfer
Manja Meggendorfer
JMJaroslaw P. Maciejewski
Jaroslaw P. Maciejewski

26 November 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
YNYasunobu Nagata
Yasunobu Nagata
HMHideki Makishima
Hideki Makishima
CKCassandra M. Kerr
Cassandra M. Kerr
BPBartlomiej P. Przychodzen
Bartlomiej P. Przychodzen
MAMai Aly
Mai Aly
JMJaroslaw P. Maciejewski
Jaroslaw P. Maciejewski
Myelodysplastic syndromes (MDS) arise in older adults through stepwise acquisitions of multiple somatic mutations. Here, analyzing 1809 MDS patients, we infer clonal architecture by using a stringent, the single-cell sequencing validated PyClone bioanalytic pipeline, and assess the position of the mutations within the clonal architecture. All 3,971 mutations are grouped based on their rank in the deduced clonal hierarchy (dominant and secondary). We evaluated how they affect the resultant morphology, progression, survival and response to therapies. Mutations of SF3B1, U2AF1, and TP53 are more likely to be dominant, those of ASXL1, CBL, and KRAS are secondary. Among distinct combinations of dominant/secondary mutations we identified 37 significant relationships, of which 12 affect clinical phenotypes, 5 cooperatively associate with poor prognosis. They also predict response to hypomethylating therapies. The clonal hierarchy has distinct ranking and the resultant invariant combinations of dominant/secondary mutations yield novel insights into the specific clinical phenotype of MDS.

1 February 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
HAHassan Awada
Hassan Awada
YNYasunobu Nagata
Yasunobu Nagata
AGAbhinav Goyal
Abhinav Goyal
MAMohammad F. Asad
Mohammad F. Asad
BPBhumika Patel
Bhumika Patel
JMJaroslaw P. Maciejewski
Jaroslaw P. Maciejewski
Somatic TET2 mutations (TET2MT) are frequent in myeloid neoplasia (MN), particularly chronic myelomonocytic leukemia (CMML). TET2MT includes mostly loss-of-function/hypomorphic hits. Impaired TET2 activity skews differentiation of hematopoietic stem cells toward proliferating myeloid precursors. This study was prompted by the observation of frequent biallelic TET2 gene inactivations (biTET2i) in CMML. We speculated that biTET2i might be associated with distinct clinicohematological features. We analyzed TET2MT in 1045 patients with MN. Of 82 biTET2i cases, 66 were biTET2MT, 13 were hemizygous TET2MT, and 3 were homozygous TET2MT (uniparental disomy); the remaining patients (denoted biTET2− hereafter) were either monoallelic TET2MT (n = 96) or wild-type TET2 (n = 823). Truncation mutations were found in 83% of biTET2i vs 65% of biTET2− cases (P = .02). TET2 hits were founder lesions in 72% of biTET2i vs 38% of biTET2− cases (P < .0001). In biTET2i, significantly concurrent hits included SRSF2MT (33%; P < .0001) and KRAS/NRASMT (16%; P = .03) as compared with biTET2−. When the first TET2 hit was ancestral in biTET2i, the most common subsequent hits affected a second TET2MT, followed by SRSF2MT, ASXL1MT, RASMT, and DNMT3AMT. BiTET2i patients without any monocytosis showed an absence of SRSF2MT. BiTET2i patients were older and had monocytosis, CMML, normal karyotypes, and lower-risk disease compared with biTET2− patients. Hence, while a second TET2 hit occurred frequently, biTET2i did not portend faster progression but rather determined monocytic differentiation, consistent with its prevalence in CMML. Additionally, biTET2i showed lower odds of cytopenias and marrow blasts (≥5%) and higher odds of myeloid dysplasia and marrow hypercellularity. Thus, biTET2i might represent an auxiliary assessment tool in MN.

22 November 2018 in Blood
Verified
Journal Article
Closed access
PDF file
YNYasunobu Nagata
Yasunobu Nagata
SNSatoshi Narumi
Satoshi Narumi
YGYihong Guan
Yihong Guan
BPBartlomiej P. Przychodzen
Bartlomiej P. Przychodzen
CHCassandra M. Hirsch
Cassandra M. Hirsch
JMJaroslaw P. Maciejewski
Jaroslaw P. Maciejewski

30 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
HAHassan Awada
Hassan Awada
MVMaria Teresa Voso
Maria Teresa Voso
PGPaola Guglielmelli
Paola Guglielmelli
CGCarmelo Gurnari
Carmelo Gurnari
Over the past decade, new insights have emerged on the pathophysiology of essential thrombocythemia (ET), its clinical management, and associated thrombohemostatic disturbances. Here, we review the latest diagnostic and risk stratification modalities of ET and its therapeutics. Moreover, we discuss the clinical evidence-based benefits, deriving from major clinical trials, of using cytoreductive therapy and antiplatelet agents to lower the risk of fatal vascular events. Also, we focus on the condition of extreme thrombocytosis (>1000 × 109/L) and bleeding risk, the development and pathogenesis of acquired von Willebrand syndrome, and the clinical approach to this paradoxical scenario in ET.

14 August 2019 in Haematologica
Verified
Journal Article
Closed access
TKTeodora Kuzmanovic
Teodora Kuzmanovic
BPBhumika J. Patel
Bhumika J. Patel
SSSrinivasa R. Sanikommu
Srinivasa R. Sanikommu
YNYasunobu Nagata
Yasunobu Nagata
HAHassan Awada
Hassan Awada
TRTomas Radivoyevitch
Tomas Radivoyevitch